$WMK

WEIS MARKETS REPORTS SECOND QUARTER 2026 RESULTS

Weis Markets (NYSE: WMK) reported Q2 2026 total revenue of $1.28 billion, up 4.6% from $1.22 billion in Q2 2025. Comparable store sales rose 2.3% year over year. Net income fell to $22.86 million, down 9.6%, and EPS was $0.92. Pharmacy revenue faced Medicare pricing headwinds. A $0.34 quarterly dividend was declared.

Original reporting
Published Aug 4, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WEIS MARKETS REPORTS SECOND QUARTER 2026 RESULTS — source image
Decision brief

The 30-second read

$WMKNeutralMed
01

Why it matters

Traders will likely focus on the divergence between improving revenue/comps and declining net income/EPS, and on the magnitude of pharmacy pricing headwinds cited for both the quarter and year-to-date.

02

Market read

A fresh earnings release with quantified pharmacy pricing headwinds and a dividend declaration, creating a near-term catalyst for WMK positioning.

03

What to watch

Two-year stacked comparable store sales improved, and management highlighted stronger performance at newer stores, which could partially offset near-term pharmacy margin pressure.

Relevance 8/10Novelty 8/10Timing: after-hours earnings release, Aug. 4, 2026

Background

Weis Markets released its 13-week Q2 2026 and 26-week year-to-date results ended June 27, 2026, including pharmacy-specific headwinds tied to IRA Medicare pricing.

Company-level read

Ticker impact

$WMKNeutralMedium confidence
Context

Weis Markets reported Q2 2026 revenue of $1.28B (+4.6%) and EPS of $0.92, down 4 cents year over year.

Expected impact

Likely modest near-term volatility as traders weigh revenue/comps strength against EPS decline and pharmacy headwinds.

Evidence & confidence

The article provides specific Q2 and YTD financial datapoints plus a concrete driver for pharmacy weakness (IRA Medicare maximum fair price provisions effective Jan 1, 2026).

Market effects

Signals ongoing pressure in pharmacy reimbursement economics for grocery retailers with Medicare Part D exposure under the IRA pricing rules.

May influence sentiment toward Mid-Atlantic grocery peers if investors extrapolate similar pharmacy headwinds and value-driven demand.

Limited, as the disclosure is company-specific and not tied to global macro or supply shocks.

Counterpoint

The EPS decline may be more about pharmacy reimbursement timing and pricing mechanics than underlying demand weakness, so the market may over-penalize the stock.

Key entities

  • Weis Markets, Inc.

    Mid-Atlantic grocery retailer reporting Q2 2026 results and a quarterly dividend.

  • Inflation Reduction Act (IRA) Medicare maximum fair price provisions

    Pricing provisions effective Jan 1, 2026 that the company cites as headwinds to pharmacy revenue.

  • Weis Markets Board of Directors

    Declared a quarterly cash dividend of $0.34 per share payable Aug. 10, 2026.

Related articles

$WMKMed

WEIS MARKETS INC (WMK): Results of Operations and Financial Condition

WEIS MARKETS INC (WMK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 wmk-20260804xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ NEWS RELEASE ​ FOR IMMEDIATE RELEASE Contact: Dennis Curtin Weis Markets, Inc. 570-847-3636 dennis.curtin@weismarkets.com ​ ​ WEIS MARKETS REPORTS SECOND QUARTER 2026 RESULTS Second Quarter 2026 total revenue increased 4.

$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.

$HLMedAI 8/10

Hecla Mining Q2 Earnings Call Highlights

Hecla Mining reported Q2 financial and operating updates. The company ended the quarter with $483 million cash, about $472 million net cash, and an essentially undrawn $225 million revolver. It projected 2026 free cash flow of about $500 million at $50 silver and $3,500 gold, and raised Greens Creek silver guidance to 8.0-8.3 million ounces. Production guidance was adjusted for Lucky Friday and Keno Hill.

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

$NETHighAI 9/10

Cloudflare shares jump after forecast raise on higher AI-driven spending

Cloudflare shares rose about 16% premarket after the company raised its full-year outlook, citing higher enterprise spending on AI infrastructure. Cloudflare now forecasts revenue of $2.86B to $2.87B and adjusted EPS of $1.25 to $1.26. Reuters also notes strong cloud growth at Amazon and rising developer additions.